DDX43 gene and tumors

Abstract

Chen Qin, Lin Jiang, Qian Jun. DDX43 gene and tumors[J]. Journal of International Oncology, 2015, 42(2): 115-117.

［1］ Martelange V, De Smet C, De Plaen E, et al. Identification on a human sarcoma of two new genes with tumorspecific expression［J］. Cancer Res, 2000, 60(14): 3848-3855. ［2］ Mathieu MG, Linley AJ, Reeder SP, et al. HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers［J］. Cancer Immun, 2010, 10: 2. ［3］ Mathieu MG, Knights AJ, Pawelec G, et al. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class Ⅰ/Ⅱ HAGEderived immunogenic peptides［J］. Cancer Immunol Immunother, 2007, 56(12): 1885-1895. ［4］ Cordin O, Banroques J, Tanner NK, et al. The DEAD box protein family of RNA helicases［J］. Gene, 2006, 367: 17-37. ［5］ Linley AJ, Mathieu MG, Miles AK, et al. The helicase HAGE expressed by malignant melanomainitiating cells is required for tumor cell proliferation in vivo［J］. J Biol Chem, 2012, 287(17): 13633-13643. ［6］ Mathieu MG, Miles AK, Ahmad M, et al. The helicase HAGE prevents interferonainduced PML expression in ABCB5+ malignant melanomainitiating cells by promoting the expression of SOCS1［J］. Cell Death Dis, 2014, 5: e1061. ［7］ Ambrosini G, Khanin R, Carvajal RD, et al. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS upregulation in uveal melanoma cells［J］. Mol Cancer Ther, 2014, 13(8): 2073-2080. ［8］ Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer［J］. Nat Rev Cancer, 2005, 5(8): 615-625. ［9］ Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy［J］. Cancer Sci, 2009, 100(11): 2014-2021. ［10］ Riley CL, Mathieu MG, Clark RE, et al. Tumour antigentargeted immunotherapy for chronic myeloid leukaemia: is it still viable?［J］. Cancer Immunol Immunother, 2009, 58(9): 1489-1499. ［11］ Nagel H, Laskawi R, Eiffert H, et al. Analysis of the tumour suppressor genes, FHIT and WT1, and the tumour rejection genes, BAGE, GAGE1/2, HAGE, MAGE1, and MAGE3, in benign and malignant neoplasms of the salivary glands［J］. Mol Pathol, 2003, 56(4): 226-231. ［12］ Adams SP, Sahota SS, Mijovic A, et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias［J］. Leukemia, 2002, 16(11): 2238-2242. ［13］ Condomines M, Hose D, Raynaud P, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis［J］. J Immunol, 2007, 178(5): 3307-3315. ［14］ Liggins AP, Lim SH, Soilleux EJ, et al. A panel of cancertestis genes exhibiting broadspectrum expression in haematological malignancies［J］. Cancer Immun, 2010, 10: 8. ［15］ Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary［J］. Cancer Immun, 2004, 4: 1. ［16］ Akiyama Y, Komiyama M, Miyata H, et al. Novel cancertestis antigen expression on glioma cell lines derived from highgrade glioma patients［J］. Oncol Rep, 2014, 31(4): 1683-1690. ［17］ AbdelFatah TM, McArdle SE, Johnson C, et al. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer［J］. Br J Cancer, 2014, 110(10): 2450-2461. ［18］ Shen L, Kondo Y, Guo Y, et al. Genomewide profiling of DNA methylation　reveals a class of normally methylated CpG island promoters［J］. PLoS Genet, 2007, 3(10): 2023-2036. ［19］ RomanGomez J, JimenezVelasco A, Agirre X, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia［J］. Haematologica, 2007, 92(2): 153-162. ［20］ Chen Q, Lin J, Qian J, et al. The methylation status of the DDX43 promoter in Chinese patients with chronic myeloid leukemia［J］. Genet Test Mol Biomarkers, 2013, 17(6): 508-511. ［21］ Chen Q, Lin J, Yao DM, et al. Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome［J］. Br J Haematol, 2012, 158(2): 293-296. ［22］ Lin J, Chen Q, Yang J, et al. DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia［J］. Leuk Res, 2014, 38(5): 601-607.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments